<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20535" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Diphenhydramine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sicari</surname>
            <given-names>Vincent</given-names>
          </name>
          <aff>Kent Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zabbo</surname>
            <given-names>Christopher P.</given-names>
          </name>
          <aff>Kent Hospital/ UNECOM</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vincent Sicari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christopher Zabbo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20535.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Diphenhydramine, which is available as an over-the-counter medication, is a first-generation antihistamine that is used in a variety of conditions to treat and prevent dystonias, insomnia, pruritis, urticaria, vertigo, and motion sickness. It also possesses local anesthetic properties for those patients who have allergies to other, more commonly used local anesthetics; however, this is an off-label use of the medication. Additional off-label use is for the treatment of oral mucositis. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of diphenhydramine, pertinent for members of the interprofessional team in the treatment of patients</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanisms of action for diphenhydramine.</p></list-item><list-item><p>Identify the approved and off-label indications for diphenhydramine use.</p></list-item><list-item><p>Review the possible adverse events associated with diphenhydramine.</p></list-item><list-item><p>Review the importance of improving care coordination among interprofessional team members to improve outcomes for patients where diphenhydramine can play a role in treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20535&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20535">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20535.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Diphenhydramine, which is available as an over-the-counter medication, is a first-generation antihistamine that is used in a variety of conditions to treat and prevent dystonias, insomnia, pruritis, urticaria, vertigo, and motion sickness. It also possesses local anesthetic properties for patients with allergies to other, more commonly used local anesthetics; however, this is an off-label use of the medication. Additional off-label use is for the treatment of oral mucositis.</p>
      </sec>
      <sec id="article-20535.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Diphenhydramine mainly works through antagonizing the H1 (histamine 1) receptor, although it has other mechanisms of action as well.<xref ref-type="bibr" rid="article-20535.r1">[1]</xref></p>
        <p>The H1 receptor is located on respiratory smooth muscles, vascular endothelial cells, the gastrointestinal tract (GIT), cardiac tissue, immune cells, the uterus, and the central nervous system (CNS) neurons. When the H1 receptor is stimulated&#x000a0;in these tissues, it produces a wide variety of actions, including increased vascular permeability, promotion of vasodilation causing flushing, decreased atrioventricular&#x000a0;(AV)&#x000a0;node conduction time, stimulation of sensory nerves of airways producing coughing, smooth muscle contraction of bronchi and GIT, and eosinophilic chemotaxis promoting the allergic immune response.</p>
        <p>Diphenhydramine acts as an inverse agonist at the H1 receptor, thereby reversing the effects of histamine on capillaries, reducing allergic reaction symptoms.&#x000a0;</p>
        <p>Given that diphenhydramine is a first-generation antihistamine, it readily crosses the blood-brain barrier and inversely agonizes the H1 CNS receptors, resulting in drowsiness and suppressing the medullary cough center.<xref ref-type="bibr" rid="article-20535.r2">[2]</xref></p>
        <p>The H1 receptor is similar to muscarinic receptors. Therefore, diphenhydramine also acts as an antimuscarinic; it is a competitive antagonist of muscarinic acetylcholine receptor, resulting in its use as an antiparkinson medication.</p>
        <p>Lastly, diphenhydramine acts as an intracellular sodium channel blocker, resulting in local anesthetic properties.</p>
        <p>The liver metabolizes diphenhydramine via CYP450. It is excreted in the urine, unchanged, and has a half-life of 3.4&#x000a0;to 9.2hours.&#x000a0;The drug's time to peak, serum is 2 hours.</p>
      </sec>
      <sec id="article-20535.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Diphenhydramine can be given by tablet, capsule, or solution by mouth; by intramuscular (IM) or intravenous (IV) injection; or topically.</p>
        <p>The following are recommended&#x000a0;dosages for allergy symptoms:</p>
        <p>
<bold>Mild Symptoms</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult
<list list-type="bullet"><list-item><p>25 to 50 mg by mouth/IM/IV every 4 to 6 hours&#x000a0;as needed</p></list-item><list-item><p>Max: 300 mg/day by mouth; 100 mg/dose up to 400 mg/day IM/IV</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Pediatric
<list list-type="bullet"><list-item><p>2 to 5 years: 6.25 mg by&#x000a0;mouth/IM/IV every 4 to 6 hours as needed; max 37.5 mg/day</p></list-item><list-item><p>6 to 11 years: 12.5&#x000a0;to 25mg by mouth/IM/IV every 4 to 6 hours as needed; max 150 mg/day</p></list-item><list-item><p>12 years and older: use adult dosing</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>More Severe Symptoms</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult
<list list-type="bullet"><list-item><p>25-50 mg by mouth/IM/IV every 2 to 4 hours as needed</p></list-item><list-item><p>Max: 300 mg/day by mouth; 100mg/dose up to 400 mg/day IM/IV</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Pediatric
<list list-type="bullet"><list-item><p>2 to 11 years: 1-2mg/kg by mouth/IM/IV every 2 to 4 hours as needed; max: 300 mg/day by mouth; 100mg/dose up to 400 mg/day IM/IV</p></list-item><list-item><p>12 yo and older: use adult dosing</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Extrapyramidal Symptoms</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>25 to 50 mg by mouth/IM/IV every 6 to 8 hours as needed</p>
          </list-item>
          <list-item>
            <p>Max 300 mg/day by mouth; 100 mg/dose up to 400 mg/day IM/IV</p>
          </list-item>
          <list-item>
            <p>Pediatric
<list list-type="bullet"><list-item><p>2 to 11 years: 1 to 2 mg/kg by mouth/IM/IV every 6 to 6 hours as needed; max: 50 mg/dose up to 300 mg/day IM/IV</p></list-item><list-item><p>12 years and older: use adult dosing</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Insomnia (Short Treatment)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>25 to 50 mg by mouth at bedtime as needed, start 30min before bedtime</p>
          </list-item>
          <list-item>
            <p>Pediatric - 12 yo and older: 25 to 50 mg by mouth&#x000a0;at bedtime as needed; start 30min before bedtime</p>
          </list-item>
        </list>
        <p>
<bold>Motion Sickness Prevention</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>25 to 50 mg by mouth/IM/IV every 4 to 6 hours as needed.</p>
          </list-item>
          <list-item>
            <p>Start 30 min before event; max 300 mg/day by mouth; 100 mg/dose up to 400 mg/day IM/IV</p>
          </list-item>
          <list-item>
            <p>Pediatric dose:
<list list-type="bullet"><list-item><p>2 to 5 years: 6.25 mg by mouth/IM/IV every 4 to 6 hours as needed; start 30 min before the event; max 37.5 mg/day</p></list-item><list-item><p>6 to 11 years: 12.5&#x000a0;to 25mg by mouth/IM/IV every 4 to 6 hours as needed; start 30 min before the event; max 150 mg/day</p></list-item><list-item><p>12 years and older: use adult dosing</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Pruritis/Urticaria</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>25 to 50 mg by mouth/IM/IV every 4 to 6 hours as needed. Max 300 mg/day by mouth; 100 mg/dose up to 400 mg/day IM/IV</p>
          </list-item>
          <list-item>
            <p>Pediatric
<list list-type="bullet"><list-item><p>2 to 5 years: 6.25 mg by mouth/IM/IV every 4 to 6 hours as needed; max 37.5 mg/day</p></list-item><list-item><p>6 to 11 years: 12.5 to 25 mg by mouth/IM/IV every 4 to 6 hours as needed; max 150 mg/day</p></list-item><list-item><p>12 years and older: use adult dosing</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Sedation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>25 to 50 mg by mouth/IM/IV every 4 to 6 hours as needed. Max 300 mg/day by mouth; 100 mg/dose up to 400 mg/day IM/IV</p>
          </list-item>
        </list>
        <p>
<bold>Pruritis/Urticaria (Topical Treatment)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Apply as needed; max 4 times/day</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For local anesthesia
<list list-type="bullet"><list-item><p>Prepare a 1% solution of diphenhydramine (10 mg/mL)</p></list-item><list-item><p>Draw up the entire contents of a vial containing 50 mg/mL diphenhydramine into a 10 mL&#x000a0;syringe. This should measure at a volume of 1 mL.&#x000a0;</p></list-item><list-item><p>Dilute the contents of the syringe with four mL of 0.9% sodium chloride to yield a final volume of 5 mL. This is now diphenhydramine 1% (10 mg/mL).<xref ref-type="bibr" rid="article-20535.r3">[3]</xref><xref ref-type="bibr" rid="article-20535.r4">[4]</xref></p></list-item><list-item><p>This use is off-label.&#x000a0;</p></list-item><list-item><p>Watch for tissue necrosis.</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20535.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Common Adverse Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Drowsiness</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Impaired coordination</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Epigastric discomfort</p>
          </list-item>
          <list-item>
            <p>Thickened bronchial secretions</p>
          </list-item>
          <list-item>
            <p>Dry mucous membranes</p>
          </list-item>
          <list-item>
            <p>CNS stimulation, paradoxical</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Euphoria</p>
          </list-item>
          <list-item>
            <p>Ataxia</p>
          </list-item>
          <list-item>
            <p>Dysuria</p>
          </list-item>
          <list-item>
            <p>Urinary retention</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Blurred vision</p>
          </list-item>
          <list-item>
            <p>Diplopia</p>
          </list-item>
          <list-item>
            <p>Palpitations</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Photosensitivity</p>
          </list-item>
          <list-item>
            <p>Diaphoresis</p>
          </list-item>
          <list-item>
            <p>Erectile dysfunction</p>
          </list-item>
          <list-item>
            <p>Early menses</p>
          </list-item>
          <list-item>
            <p>Anorexia</p>
          </list-item>
        </list>
        <p>Serious Reactions</p>
        <list list-type="bullet">
          <list-item>
            <p>Anaphylaxis/anaphylactoid reaction</p>
          </list-item>
          <list-item>
            <p>QT prolongation</p>
          </list-item>
          <list-item>
            <p>Anemia, hemolytic</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Agranulocytosis</p>
          </list-item>
          <list-item>
            <p>Leukopenia</p>
          </list-item>
          <list-item>
            <p>Pancytopenia</p>
          </list-item>
          <list-item>
            <p>Arrhythmias</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Toxic psychosis</p>
          </list-item>
          <list-item>
            <p>Labyrinthitis, acute</p>
          </list-item>
          <list-item>
            <p>Heatstroke</p>
          </list-item>
        </list>
        <p>
<bold>Cautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>May cause postrenal obstruction, which can lead to urinary retention and thus decreased glomerular filtration rate. If acute kidney injury&#x000a0;develops, discontinue diphenhydramine and begin supportive care for acute kidney injury if needed.<xref ref-type="bibr" rid="article-20535.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>May cause CNS depression, which can impair driving or operating heavy machinery.</p>
          </list-item>
          <list-item>
            <p>May potentiate the effects of sedatives, including alcohol.</p>
          </list-item>
          <list-item>
            <p>Considered high-risk medication for elderly patients because of increased fall risk from dizziness, sedation, and hypotension.</p>
          </list-item>
          <list-item>
            <p>Inhibition of fast sodium channels and repolarizing potassium channels (Ikr) can prolong the action potential and the QT interval, leading to QTc prolongation.<xref ref-type="bibr" rid="article-20535.r6">[6]</xref><xref ref-type="bibr" rid="article-20535.r7">[7]</xref><xref ref-type="bibr" rid="article-20535.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Use caution in patients with asthma, hyperthyroidism, cardiovascular disease, hypertension, or increased ocular pressure.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20535.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>Documented hypersensitivity to diphenhydramine</p>
          </list-item>
          <list-item>
            <p>Premature infants and neonates</p>
          </list-item>
          <list-item>
            <p>Breastfeeding mothers</p>
          </list-item>
          <list-item>
            <p>Pregnancy Category B - used only if clearly needed</p>
          </list-item>
          <list-item>
            <p>Diphenhydramine has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers)</p>
          </list-item>
          <list-item>
            <p>Monoamine oxidase A&#x000a0;inhibitors prolong and intensify the anticholinergic effects of antihistamines</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20535.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Obtain&#x000a0;baseline creatinine level in pediatric patients.</p>
        <p>Monitor all patients for mental alertness and relief of symptoms.</p>
        <p>The intravenous infusion rate should be no higher than 25 mg/min.</p>
        <p>Store at room temperature of 15 to 30 degrees C and protect from freezing and light.</p>
      </sec>
      <sec id="article-20535.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Diphenhydramine overdose<xref ref-type="bibr" rid="article-20535.r9">[9]</xref><xref ref-type="bibr" rid="article-20535.r10">[10]</xref> can cause significant toxicity, ranging from agitation to cardiac arrhythmias<xref ref-type="bibr" rid="article-20535.r11">[11]</xref> to rhabdomyolysis and classic anticholinergic toxidrome.<xref ref-type="bibr" rid="article-20535.r12">[12]</xref>&#x000a0;Signs and symptoms may include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Delirium, agitation, confusion, restlessness, hallucinations, ataxia, tremor, seizure</p>
          </list-item>
          <list-item>
            <p>Dry sweat glands and mucous membranes</p>
          </list-item>
          <list-item>
            <p>Flushed skin</p>
          </list-item>
          <list-item>
            <p>Elevated body temperature</p>
          </list-item>
          <list-item>
            <p>Mydriasis and blurry vision</p>
          </list-item>
          <list-item>
            <p>Urinary retention</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Rhabdomyolysis</p>
          </list-item>
        </list>
        <p>Treatment involves the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>May attempt activated charcoal if within 1 hour of ingestion</p>
          </list-item>
          <list-item>
            <p>Benzodiazepines for agitation and seizures; however, phenobarbital and propofol, may be needed (avoid phenytoin/fosphenytoin, as they further block sodium channels)</p>
          </list-item>
          <list-item>
            <p>Sodium bicarbonate for widened QRS to overcome sodium channel blockade; 2 mEq/kg, typically 2 to 3 amps of bicarb, then continuous infusion. Mix 3 ampules of sodium bicarbonate in 1L D5W, and run this infusion at 250 mL/hr.</p>
          </list-item>
          <list-item>
            <p>Magnesium sulfate should be administered intravenously for prolonged QT interval.</p>
          </list-item>
          <list-item>
            <p>Vasopressors if hypotension develops</p>
          </list-item>
          <list-item>
            <p>May consider physostigmine (acetylcholinesterase inhibitor that binds reversibly to inhibit acetylcholinesterase in the central and peripheral nervous system, which in turn allows acetylcholine to bind to muscarinic receptors to overcome the anticholinergic block.&#x000a0; This should be given in concert with medical toxicologist/poison control.
<list list-type="bullet"><list-item><p>Dose: 0.5 to 2 mg IV over 5 min, onset within 20 min</p></list-item><list-item><p>Have atropine at the bedside, and watch for bradycardia</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Further studies are needed to investigate the potential treatment of diphenhydramine toxicity using sodium bicarbonate and intravenous lipid emulsion therapy.<xref ref-type="bibr" rid="article-20535.r13">[13]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20535.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diphenhydramine is now available over the counter, but that does not mean that interprofessional healthcare team members should not pay close attention to when patients are using it, particularly if they are self-medicating;&#x000a0;the clinician (MD, DO, NP, PA), nurse, and pharmacist needs to educate the patient on the safe use of this agent. While the drug is relatively safe, it should not be combined with alcohol, other sedatives, and hypnotics. The&#x000a0;patient must be taught how to read labels and not take more than the recommended dose. Parents should be educated on the safe storage of this agent to prevent accidental ingestion by children. Interprofessional collaboration and information sharing will result in improved patient outcomes and help to preclude adverse events. [Level 5]</p>
      </sec>
      <sec id="article-20535.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20535&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20535">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20535/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20535">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20535.s11">
        <title>References</title>
        <ref id="article-20535.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Church</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of antihistamines.</article-title>
            <source>Indian J Dermatol</source>
            <year>2013</year>
            <month>May</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>219</fpage>
            <page-range>219-24</page-range>
            <pub-id pub-id-type="pmid">23723474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20535.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bolser</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Older-generation antihistamines and cough due to upper airway cough syndrome (UACS): efficacy and mechanism.</article-title>
            <source>Lung</source>
            <year>2008</year>
            <volume>186 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>S74</fpage>
            <page-range>S74-7</page-range>
            <pub-id pub-id-type="pmid">17909896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20535.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>What is the role of diphenhydramine in local anesthesia?</article-title>
            <source>Acad Emerg Med</source>
            <year>1996</year>
            <month>Mar</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>198</fpage>
            <page-range>198-200</page-range>
            <pub-id pub-id-type="pmid">8673772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20535.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pavlidakey</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Brodell</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Helms</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Diphenhydramine as an alternative local anesthetic agent.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>2</volume>
            <issue>10</issue>
            <fpage>37</fpage>
            <page-range>37-40</page-range>
            <pub-id pub-id-type="pmid">20725573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20535.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pham</surname>
                <given-names>AQ</given-names>
              </name>
              <name>
                <surname>Scarlino</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Diphenhydramine and acute kidney injury.</article-title>
            <source>P T</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>453</fpage>
            <page-range>453-61</page-range>
            <pub-id pub-id-type="pmid">24222977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20535.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sype</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>IA</given-names>
              </name>
            </person-group>
            <article-title>Prolonged QT interval with markedly abnormal ventricular repolarization in diphenhydramine overdose.</article-title>
            <source>Int J Cardiol</source>
            <year>2005</year>
            <month>Mar</month>
            <day>18</day>
            <volume>99</volume>
            <issue>2</issue>
            <fpage>333</fpage>
            <page-range>333-5</page-range>
            <pub-id pub-id-type="pmid">15749198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20535.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Husain</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Steinman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Diphenhydramine induced QT prolongation and torsade de pointes: An uncommon effect of a common drug.</article-title>
            <source>Cardiol J</source>
            <year>2010</year>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>509</fpage>
            <page-range>509-11</page-range>
            <pub-id pub-id-type="pmid">20865683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20535.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olasi&#x00144;ska-Wi&#x0015b;niewska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olasi&#x00144;ski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grajek</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular safety of antihistamines.</article-title>
            <source>Postepy Dermatol Alergol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>182</fpage>
            <page-range>182-6</page-range>
            <pub-id pub-id-type="pmid">25097491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20535.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radovanovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Guirguis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lorent</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kupferschmidt</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Dose-dependent toxicity of diphenhydramine overdose.</article-title>
            <source>Hum Exp Toxicol</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>489</fpage>
            <page-range>489-95</page-range>
            <pub-id pub-id-type="pmid">11204550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20535.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krenzelok</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Mirick</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Massive diphenhydramine overdose resulting in death.</article-title>
            <source>Ann Emerg Med</source>
            <year>1982</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>212</fpage>
            <page-range>212-3</page-range>
            <pub-id pub-id-type="pmid">7073039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20535.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zareba</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Rosero</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Hajj-Ali</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Konecki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Electrocardiographic findings in patients with diphenhydramine overdose.</article-title>
            <source>Am J Cardiol</source>
            <year>1997</year>
            <month>Nov</month>
            <day>01</day>
            <volume>80</volume>
            <issue>9</issue>
            <fpage>1168</fpage>
            <page-range>1168-73</page-range>
            <pub-id pub-id-type="pmid">9359544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20535.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000f6;ppel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ibe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tenczer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical symptomatology of diphenhydramine overdose: an evaluation of 136 cases in 1982 to 1985.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>1987</year>
            <volume>25</volume>
            <issue>1-2</issue>
            <fpage>53</fpage>
            <page-range>53-70</page-range>
            <pub-id pub-id-type="pmid">3586086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20535.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diphenhydramine overdose with intraventricular conduction delay treated with hypertonic sodium bicarbonate and i.v. lipid emulsion.</article-title>
            <source>West J Emerg Med</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>855</fpage>
            <page-range>855-8</page-range>
            <pub-id pub-id-type="pmid">25493135</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
